The CSF1R inhibitors pexidartinib and vimseltinib are approved in the United States for adult patients with TGCT not amenable to surgery, and several other agents are in clinical development. The gene discussed is CSF1R; the disease is tenosynovial giant cell tumor, diffuse type.